Atul Pande
CIK: 0001643071
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Immunovant, Inc.
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Aug 28, 2026IMVT
Immunovant, Inc.
Sale(S)Direct1.5K shares at avg. $43.27$65K - Aug 28, 2026IMVT
Immunovant, Inc.
Exercise(M)Direct1.5K shares at avg. $8.43$13K - Jul 24, 2026IMVT
Immunovant, Inc.
Sale(S)Direct1.5K shares at avg. $39.80$60K - Jul 24, 2026IMVT
Immunovant, Inc.
Exercise(M)Direct1.5K shares at avg. $8.43$13K - Jun 26, 2026IMVT
Immunovant, Inc.
Exercise(M)Direct1.5K shares at avg. $8.43$13K - Jun 26, 2026IMVT
Immunovant, Inc.
Sale(S)Direct1.5K shares at avg. $38.01$57K - Jun 15, 2026IMVT
Immunovant, Inc.
Exercise(M)Direct1.5K shares at avg. $8.43$13K - Jun 15, 2026IMVT
Immunovant, Inc.
Sale(S)Direct1.5K shares at avg. $34.02$51K - May 20, 2026IMVT
Immunovant, Inc.
Exercise(M)Direct6K shares at avg. $8.43$51K - May 20, 2026IMVT
Immunovant, Inc.
Sale(S)Direct6K shares at avg. $32.00$192K - Apr 7, 2026IMVT
Immunovant, Inc.
Award(A)Direct13.9K shares- - Apr 1, 2025IMVT
Immunovant, Inc.
Award(A)Direct16.2K shares- - Dec 2, 2024IMVT
Immunovant, Inc.
Sale(S)Direct7.8K shares at avg. $28.54$221K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 28, 2026 | IMVT Immunovant, Inc. | Sale(S) | 1,500 | $43.27 | $64,905 | Direct |
| Aug 28, 2026 | IMVT Immunovant, Inc. | Exercise(M) | 1,500 | $8.43 | $12,645 | Direct |
| Jul 24, 2026 | IMVT Immunovant, Inc. | Sale(S) | 1,500 | $39.80 | $59,700 | Direct |
| Jul 24, 2026 | IMVT Immunovant, Inc. | Exercise(M) | 1,500 | $8.43 | $12,645 | Direct |
| Jun 26, 2026 | IMVT Immunovant, Inc. | Exercise(M) | 1,500 | $8.43 | $12,645 | Direct |
| Jun 26, 2026 | IMVT Immunovant, Inc. | Sale(S) | 1,500 | $38.01 | $57,015 | Direct |
| Jun 15, 2026 | IMVT Immunovant, Inc. | Exercise(M) | 1,500 | $8.43 | $12,645 | Direct |
| Jun 15, 2026 | IMVT Immunovant, Inc. | Sale(S) | 1,500 | $34.02 | $51,030 | Direct |
| May 20, 2026 | IMVT Immunovant, Inc. | Exercise(M) | 6,000 | $8.43 | $50,580 | Direct |
| May 20, 2026 | IMVT Immunovant, Inc. | Sale(S) | 6,000 | $32.00 | $192,000 | Direct |
| Apr 7, 2026 | IMVT Immunovant, Inc. | Award(A) | 13,880 | - | $0 | Direct |
| Apr 1, 2025 | IMVT Immunovant, Inc. | Award(A) | 16,188 | - | - | Direct |
| Dec 2, 2024 | IMVT Immunovant, Inc. | Sale(S) | 7,750 | $28.54 | $221,185 | Direct |
1-13 of 13 transactions
About Pande Atul
Pande Atul (SEC CIK 0001643071) files insider reports with the SEC as Director of Immunovant, Inc. (IMVT).
Signal8 holds 8 ownership filings by Pande Atul, all Form 4s, filed between Dec 4, 2024 and Aug 28, 2026. Those filings report 13 transactions, from Dec 2, 2024 to Aug 28, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Pande Atul's filings is in DURHAM, NC.
Recent filings by Pande Atul
- Aug 28, 2026: Open-market sale of IMVT shares (Form 4, code S).
- Aug 28, 2026: Option exercise of IMVT shares (Form 4, code M).
- Jul 24, 2026: Open-market sale of IMVT shares (Form 4, code S).
- Jul 24, 2026: Option exercise of IMVT shares (Form 4, code M).
- Jun 26, 2026: Option exercise of IMVT shares (Form 4, code M).
Other insiders filing for Immunovant, Inc. (IMVT)
- Girao Tiago, Chief Financial Officer
- Stout Jay S, Chief Technology Officer
- Van Tuyl Christopher, Chief Legal Officer
- Gloria Melanie, Chief Operating Officer
- Venker Eric, Chief Executive Officer
- Fromkin Andrew J., Director